Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination

Giedre Gefenaite; Margot Tacken; Jens Bos; Irina Stirbu-Wagner; Joke C. Korevaar; Ronald P. Stolk; Bert Wolters; Marc Bijl; Maarten J. Postma; Jan Wilschut; Kristin L. Nichol; Eelko Hak

doi:10.1371/journal.pone.0066125

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination

Giedre Gefenaite^*, Margot Tacken, Jens Bos, Irina Stirbu-Wagner, Joke C. Korevaar, Ronald P. Stolk, Bert Wolters, Marc Bijl, Maarten J. Postma, Jan Wilschut, Kristin L. Nichol, Eelko Hak

^*Corresponding author for this work

Life Course Epidemiology (LCE)

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

277 Downloads (Pure)

Abstract

INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.

METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.

RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.

CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

Original language	English
Article number	e66125
Number of pages	6
Journal	PLoS ONE
Volume	8
Issue number	6
DOIs	https://doi.org/10.1371/journal.pone.0066125
Publication status	Published - 20-Jun-2013

Keywords

Adjuvants, Immunologic
Adolescent
Adult
Case-Control Studies
Female
Humans
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
Influenza, Human
Male
Middle Aged
Netherlands
Polysorbates
Retrospective Studies
Squalene
Vaccination
Young Adult

Access to Document

10.1371/journal.pone.0066125Licence: CC BY

Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza VaccinationFinal publisher's version, 368 KBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{93863b5a34bc4347b5ed966232153d6b,

title = "Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination",

abstract = "INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.",

keywords = "Adjuvants, Immunologic, Adolescent, Adult, Case-Control Studies, Female, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Netherlands, Polysorbates, Retrospective Studies, Squalene, Vaccination, Young Adult",

author = "Giedre Gefenaite and Margot Tacken and Jens Bos and Irina Stirbu-Wagner and Korevaar, {Joke C.} and Stolk, {Ronald P.} and Bert Wolters and Marc Bijl and Postma, {Maarten J.} and Jan Wilschut and Nichol, {Kristin L.} and Eelko Hak",

year = "2013",

month = jun,

day = "20",

doi = "10.1371/journal.pone.0066125",

language = "English",

volume = "8",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "PUBLIC LIBRARY SCIENCE",

number = "6",

}

TY - JOUR

T1 - Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination

AU - Gefenaite, Giedre

AU - Tacken, Margot

AU - Bos, Jens

AU - Stirbu-Wagner, Irina

AU - Korevaar, Joke C.

AU - Stolk, Ronald P.

AU - Wolters, Bert

AU - Bijl, Marc

AU - Postma, Maarten J.

AU - Wilschut, Jan

AU - Nichol, Kristin L.

AU - Hak, Eelko

PY - 2013/6/20

Y1 - 2013/6/20

N2 - INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

AB - INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

KW - Adjuvants, Immunologic

KW - Adolescent

KW - Adult

KW - Case-Control Studies

KW - Female

KW - Humans

KW - Influenza A Virus, H1N1 Subtype

KW - Influenza Vaccines

KW - Influenza, Human

KW - Male

KW - Middle Aged

KW - Netherlands

KW - Polysorbates

KW - Retrospective Studies

KW - Squalene

KW - Vaccination

KW - Young Adult

U2 - 10.1371/journal.pone.0066125

DO - 10.1371/journal.pone.0066125

M3 - Article

C2 - 23840413

SN - 1932-6203

VL - 8

JO - PLoS ONE

JF - PLoS ONE

IS - 6

M1 - e66125

ER -

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this